The CREST-2 Registry

Recruiting now

Conditions studied: Carotid Artery Diseases

In brief

The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists' eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure. The safety and quality results from C2R will guide selection of interventionists for participation in the CREST-2 randomized clinical trial. Enrollment into C2R will begin in 2015 and continue until publication of the primary results of the randomized trial.

Key facts

Study ID

NCT02240862

Run by

University of Maryland, Baltimore

People needed

8000

Starts

2015-02-01

Expected to finish

2027-01-31

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Asymptomatic patients:
• Age ≥ 18 and ≤ 80 and any one of the following
• ≥70% stenosis, standard surgical risk for CEA
• ≥70% stenosis, high anatomic risk for CEA
• ≥70% stenosis, high physiologic risk for CEA
• Symptomatic patients:
• Symptomatic patients are defined by the following characteristics: Ipsilateral carotid Transient Ischemic Attack (TIA), with neurologic symptoms persisting less than 24 hours; Ipsilateral non-disabling stroke: Modified Rankin Scale (mRS) ≤ 3; and Ipsilateral transient monocular blindness: amaurosis fugax. [Source: current Medicare NCD for CAS]
• Age ≥ 18 and ≤ 80 and any one of the following
• ≥50% stenosis, standard surgical risk for CEA
• 50% to 69% stenosis, high anatomic risk for CEA
• 50% to 69% stenosis, high physiologic risk
• ≥70% stenosis, high anatomic and/or physiologic risk for CEA - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R
• ≥70% stenosis, post-CEA and -CAS - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R
• ≥70% stenosis, post-irradiation - currently covered by Medicare, but sites are strongly encouraged to voluntarily include these patients in C2R

You may not qualify if…

• Patients with any one of the following conditions are ineligible for enrollment in C2R
• NYHA Class IV CHF
• COPD on chronic continuous oxygen therapy
• Severe (Class Childs D) liver failure
• End-stage renal failure requiring dialysis
• Cancer with metastatic spread and/or undergoing active chemotherapeutic treatment
• Any dementia considered greater than "mild"

Where it is running

• University of Maryland - Administrative Center — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.